Capricor Therapeutics, Inc.
CAPRNASDAQHealthcare● Active
$26.16
$-0.55(-2.06%)
Market Cap$1.2B
P/E Ratio—
52W High$40.37
52W Low$4.3
Capricor Therapeutics, Inc. (CAPR) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CAPR · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.02B | $0.03B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.05B | $0.04B | $0.02B | $0.00B |
| Gross Profit | $0.00B | ($0.03B) | ($0.01B) | ($0.02B) | $0.00B |
| Gross Margin %(computed) | — | -124.37% | -44.76% | -755.07% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.08B | $0.05B | $0.04B | $0.02B | $0.01B |
| G&A Expenses | $0.00B | $0.01B | $0.01B | $0.01B | $0.01B |
| Total Operating Expenses | $0.11B | $0.01B | $0.01B | $0.01B | $0.02B |
| Operating Income | ($0.11B) | ($0.04B) | ($0.02B) | ($0.03B) | ($0.02B) |
| Operating Margin %(computed) | — | -191.13% | -95.63% | — | — |
| Interest Income | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.11B) | ($0.04B) | ($0.02B) | ($0.03B) | ($0.02B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.11B) | ($0.04B) | ($0.02B) | ($0.03B) | ($0.02B) |
| Net Margin %(computed) | — | -181.71% | -88.52% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.26 | $-1.15 | $-0.83 | $-1.18 | $-0.87 |
| Wtd Avg Shares | 0.05B | 0.04B | 0.03B | 0.02B | 0.02B |
| EBITDA | ($0.11B) | ($0.04B) | ($0.02B) | ($0.03B) | ($0.02B) |
| EBITDA Margin %(computed) | — | -184.73% | -91.39% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Capricor Therapeutics, Inc. data
About Capricor Therapeutics, Inc. (CAPR) Income Statement
Capricor Therapeutics, Inc. (CAPR) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CAPR reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.11B) — a net profit margin of —.
Frequently asked questions
CAPR · 4 questionsCapricor Therapeutics, Inc. (CAPR) reported revenue of $0.00B for 2025, down 100.0% year-over-year.
CAPR revenueCAPR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08